Elisavet Serti Chrisos, MSc, Ph.D. is the Associate Director of Vaccines and Prevention at MHRP. Dr. Serti Chrisos has a strong background in clinical trials of vaccines and therapeutics of infectious and autoimmune diseases. She was previously a Project Leader for Vaccines and Infectious Diseases at the Emmes Corporation as well as the Associate Director of Biomarker Discovery and Research at the Immune Tolerance Network (Massachusetts General Hospital). She worked as Research Fellow and trained as a Post-Doctoral Fellow at the Immunology Section of the Liver Diseases branch of NIDDK/NIH for 6 years where she worked on clinical studies on hepatitis C infected patients with the goal of increasing treatment response of direct-acting antivirals.
Dr. Serti Chrisos received her bachelor’s degree in Biology from University of Patras in Greece (2004). She then attended University of Athens, Greece where she obtained her master’s in clinical Biochemistry and Molecular Diagnostics and her Ph.D. in Molecular Virology and Epidemiology (2011). Dr. Serti Chrisos is a member of the American Association of Virology (AAV), Federation of Clinical Immunology Societies (FOCIS), American Association for the Advancement of Science (AAAS), Society for Natural Immunity (SNI), American Association of Liver Disease (AASLD), American Association of Immunology (AAI) and a member and former President of Hellenic Bioscientific Association (HBA-USA). She is certified in Ethical and Regulatory Aspects of Clinical Research from the Maryland Nurses Association (2016) and in Technology Transfer and Patent Law from FAES NIH Graduate School (2021).
She has been recognized with several awards including the Norman P. Salzman Memorial Award in Virology for outstanding contribution in the field of Virology (2015), the NIH Director’s award for outstanding accomplishments as member of the NIH Ebola Patient Care Response Team (2015) and the Nancy Nossal Fellowship Award for Outstanding Grant Writing and Biomedical Research (2015).
E. Serti*, E. Diggins*, V. Muir, M. Rosasco, T. Lu, E. Balmas, GT. Nepom, SA. Long, and PS. Linsley. Distinct exhausted-like CD8 T cell populations are linked to C-peptide preservation in alefacept-treated, recent onset type 1 diabetes subjects. JCI Insight 2021 Feb 8;6(3):142680.
Greenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, DiMeglio LA, Herold KC, Moore WV, Goland R, Harris M, Craig ME, Schatz DA, Baidal DA, Rodriguez H, Utzschneider KM, Nel HJ, Soppe CL, Boyle KD, Cerosaletti K, Keyes-Elstein L, Long SA, Thomas R, McNamara JG, Buckner JH, Sanda S; ITN058AI EXTEND Study Team. IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. JCI Insight. 2021 Nov 8;6(21):e150074
Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, Geyer SM, Moran A, Greenbaum CJ, Evans-Molina C, Herold KC; Type 1 Diabetes TrialNet Study Group. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021 Mar 3;13(583):eabc8980.
Serti E, Park H, et al ‘Rapid decrease in viremia by direct acting antivirals improves the Innate Immune response to IFN-a’ Gut. 2017 Apr; 66(4):724-735.
Serti E, Chepa-Lotrea X, et al, ‘Successful IFN-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function’ Gastroenterology. 2015 Jul;149(1):190-200.e2.
Serti E*, Werner J*, et al, ‘Monocytes sense HCV-replicating cells and induce natural killer cell antiviral activity in an IL-18 mediated manner’ Gastroenterology 2014 Jul;147(1):209-220.
Werner J*, Serti E*, et al, ‘Ribavirin resets the STAT4-dependent IFN-γ responsiveness of natural killer cells in Hepatitis C Virus-infected patients’. Hepatology 2014 Feb 23. doi: 10.1002/hep.27092.
Serti E*, Doumba PP*, et al, ‘Phenotypic and functional alterations of primary human PBMCs induced by HCV non-enveloped capsid-like particles uptake’. Cell Mol Life Sci. 2013 Sep;70(18): 3463-74.
Park H, Serti E, et al, IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology. 2012 Dec; 56(6): 2060-70.
Serti E, et al, “Modulation of IL-2 expression after uptake of hepatitis C virus non-enveloped capsid-like particles: the role of p38 kinase” Cell Mol Life Sci. 2011 Feb; 68(3): 505-22.